COVID-19 studies are our top priority.

For new and updated trial submissions, we are processing trials as quickly as possible and appreciate your patience. We recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/show/NCT05041114




Registration number
NCT05041114
Ethics application status
Date submitted
1/09/2021
Date registered
10/09/2021
Date last updated
10/09/2021

Titles & IDs
Public title
STENTRODEā„¢ WITH THOUGHT CONTROLLED DIGITAL SWITCH: An Early Feasibility Study (EFS) of the Safety of an Endovascular Motor NeuroProsthesis (MNP) Device in Participants With Severe Upper Limb Impairment.
Scientific title
STENTRODEā„¢ WITH THOUGHT CONTROLLED DIGITAL SWITCH: An Early Feasibility Study (EFS) of the Safety of an Endovascular Motor NeuroProsthesis (MNP) Device in Participants With Severe Upper Limb Impairment.
Secondary ID [1] 0 0
SWITCH II
Universal Trial Number (UTN)
Trial acronym
SWITCH
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Neurologic Disorder 0 0
Condition category
Condition code

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Devices - Motor Neuroprosthesis

Other: Single - Implantation of motor neuroprosthesis medical device.


Treatment: Devices: Motor Neuroprosthesis
Type of implantable brain computer interface

Intervention code [1] 0 0
Treatment: Devices
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Treatment related adverse events
Timepoint [1] 0 0
12 months post implant

Eligibility
Key inclusion criteria
1. Severe motor impairment

2. Able to give consent

3. Appropriate candidate for neurointerventional procedure

4. Able and willing to access all clinical testing and not impeded by geographical
location

5. Proficient in English

6. Have a study partner
Minimum age
18 Years
Maximum age
75 Years
Gender
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Active condition resulting in immunosuppression

2. Unsuitable for general anaesthetic

3. Anaphylactic allergy to contrast media

4. Allergy to nickel

5. History of pulmonary embolism

6. History of recent deep vein thrombosis

7. Psychiatric or psychological disorder

8. Unable to provide evidence of COVID vaccination

Study design
Purpose of the study
Treatment
Allocation to intervention
N/A
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Not Applicable
Type of endpoint(s)
Statistical methods / analysis

Recruitment
Recruitment status
Not yet recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
VIC
Recruitment hospital [1] 0 0
Melbourne Health - Melbourne
Recruitment postcode(s) [1] 0 0
3050 - Melbourne

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Synchron Medical, Inc
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The Synchron motor neuroprosthesis (MNP) is intended to be used in subjects with severe motor
impairment, unresponsive to medical or rehabilitative therapy and a persistent functioning
motor cortex. The purpose of this research is to find out if the MMP device is safe in
humans.

The MNP is a type of implantable brain computer interface which bypasses dysfunctional motor
neurons. The device is designed to restore the transmission of neural signal from the
cerebral cortex utilised for neuromuscular control of digital devices, resulting in a
successful execution of non-mechanical digital commands.
Trial website
https://clinicaltrials.gov/show/NCT05041114
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Sue Dal Sasso
Address 0 0
Country 0 0
Phone 0 0
+613 93427000
Fax 0 0
Email 0 0
sue.dalsasso@mh.org.au
Contact person for scientific queries

Summary results
For IPD and results data, please see https://clinicaltrials.gov/show/NCT05041114